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INTRODUCTION
Amino acids and other nutrients are supplied to the 
inside of cells via transporters on the cell membrane. 
The incorporation of required nutrients is increased in 
cells that proliferate abundantly, such as cancer cells. 
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SUMMARY
In cells that proliferate abundantly, such as cancer cells, the expressions of many nutrient transporters 
increase in order to drive the uptake of required nutrients. The system L transporters are the main sodi-
um-independent neutral amino acid transporters. They have four isoforms：L-type amino acid transporter 
（LAT） 1, 2, 3, and 4. The expression of LAT1 has been reported in lines of cultured choriocarcinoma cells. 
However, the role of LAT1 in choriocarcinomas has not been adequately clarified. This study examined the 
role of LAT1 in these cell lines JAR and JEG-3.
Based on an examination of mRNA and protein expression, it was determined that both JAR and JEG-3 
cells express LAT1. The uptake of leucine, a substrate of LATs, by JAR and JEG-3 cells showed that 
there are sodium-independent leucine transport. To examine whether leucine transport is mediated by 
LAT1, a leucine uptake was examined with loading of JPH203, a LAT1 specific inhibitor, and transport 
inhibition was clearly seen. Cell counts were measured to examine whether cell proliferation was decreased 
by JPH203 treatment. Inhibition of JEG-3 cell proliferation was seen on day 4 of the treatment. No inhibi-
tion of JAR cell proliferation was seen by low concentrations of JPH203, however inhibition was seen on a 
higher concentration of JPH203. JPH203 decreased cell activity concentration-dependently in JEG-3 cells. 
JAR cell, however, showed an increased activity following JPH203 treatment at low concentrations. Thus, 
the study found that LAT1-mediated amino acid transport occurs in these two different lines of cultured 
choriocarcinoma cells. Moreover, it showed that the two types of cells responded differently with respect to 
inhibition of cell proliferation and changes in cell activity as a result of inhibition of LAT1-mediated amino 
acid transport. The results showed that LAT1-mediated amino acid transport in choriocarcinoma is com-
plex and has a variety of functions.
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The expression of transporters of many nutrients has 
been reported to be increased in cancer cells 1）. The 
main sodium-independent neutral amino acid trans-
porters are the system L 2）. System L has four iso-
forms：L-type amino acid transporter （LAT） 1, 2, 3, 
and 4. LAT1 was discovered in 1998 3,4）, and LAT1 
and LAT2 form heterodimers with the ancillary sub-
unit 4F2hc （CD98） when transporting amino acids 
through the cell membrane 3,5）. LAT3 and LAT4, on 
the other hand, transport amino acids independently. 
However, LAT1 and LAT2 have a greater capacity 
for transport 2,6,7）.
JPH203 （KYT0353） is a tyrosine analog that selec-
tively inhibits amino acid transport by LAT18）. The 
specific inhibition of LAT1 has been reported to 
potently inhibit the proliferation of various cancer cell 
culture lines, particularly human enterocytes, in both 
in vitro and in vivo models 8）. JPH203 has recently 
been found to inhibit leucine uptake and cell prolifera-
tion and thereby exhibit anticancer activity in human 
oral cancer cells 9） and leukemia cells 10）. JPH203 has 
shown little toxicity for normal mouse thymocytes 
and human peripheral blood cells 10）, so, cancer thera-
pies using JPH203 are therefore anticipated. Conse-
quently, clinical trials are currently being conducted 
using JPH203 as an anticancer drug.
Choriocarcinomas are tumors that occur as a result 
of malignant conversion of trophoblastic cells, and 
BeWo cells, a line of cultured choriocarcinoma cells, 
have been found to express LAT1 11）. Treatment of 
BeWo cells with 2-aminobicyclo-（2,2 ,1）-heptane-
2-carboxylic acid （BCH）, which is an inhibitor of 
LATs, has been found to induce apoptosis and autoph-
agy 12）. However, the role of LAT1 in individual cho-
riocarcinoma cells has not been adequately clarified. 
Moreover, although chemotherapy is often used to 
treat choriocarcinomas, the prognosis is poor for che-
moresistant patients 13）. Consequently, it is important 
to develop an anticancer agent that is effective against 
choriocarcinomas, and examining whether JPH203 
inhibits choriocarcinoma cell proliferation may yield 
findings of value for the treatment of choriocarcino-
mas in the future.
As a preliminary step in investigating the role of 
LAT1 in choriocarcinomas, this study examined the 
physiological role of LAT1 in JAR and JEG-3 cells, 
which are lines of cultured choriocarcinoma cells.
METHODS
Reagents
JPH203 and anti-LAT1 antibodies were provided 
by J-Pharma Co., Ltd （Tokyo, Japan）. JPH203 was 
dissolved in 10％ DMSO/EtOH for use in the tests.
Culture cells
Human gestational choriocarcinoma JAR cells 
（HTB-144） and JEG-3 cells （HTB-36） were pur-
chased from American Type Culture Collection 
（ATCC, Manassas, VA, USA）. The JAR cells were 
grown in RPMI-1640 medium （Sigma-Aldrich, St. 
Louis , MO, USA） supplemented with 2 3 . 8 mM 
NaHCO3 and 10％ fetal bovine serum （FBS）. The 
JEG-3 cells were grown in Minimum Essential Medi-
um Eagle （Sigma-Aldrich） supplemented with 
26.2 mM NaHCO3 and 10％ FBS. The cell lines were 
cultured in an incubator at 37℃ under 5％ CO2.
Reverse transcription polymerase chain reaction  
（RT-PCR）, quantitative RT-PCR
The RNeasy Mini kit （QIAGEN, Hilden, Germany） 
was used to extract mRNA from the JAR and JEG-3 
cells. The experimental method is described in the 
package insert. Genomic removal was applied to the 
extracted mRNA （2 µg）, and cDNA synthesis was 
performed using reverse transcriptase. The genomic 
removal and cDNA synthesis were performed as 
described in the package insert using the PrimeScript 
RT Reagent Kit with gDNA Eraser （Takara Bio Inc., 
Shiga, Japan）.
RT-PCR was performed using a Thermal Cycler 
Dice Touch （Takara Bio Inc.） with PCR Master Mix 
（Promega, Madison, WI, USA）. Primer was added to a 
final concentration of 0.5 µM in the reaction solution. 
The primer sequences used are shown in Table 1. 
The PCR conditions consisted of initial denaturation 
for 2 min at 95℃, followed by three steps that were 
repeated for 30 rounds：30 s at 95℃, 30 s at 55℃, 
and 30 s at 72℃. Finally, the reaction was incubated 
for 5 min at 72℃. Beta-actin was used as the internal 
control.
The quantitative RT-PCR reaction was performed 
using SYBR® Fast qPCR Mix （Takara Bio Inc.） with 
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the Thermal Cycler Dice Real Time System II （Taka-
ra Bio Inc.）. Primer was added to a final concentration 
of 0 . 4 µM in the reaction solution. The primer 
sequences used are shown in Table 2. The PCR condi-
tions consisted of initial denaturation for 30 s at 95℃, 
followed by incubation of the reaction for 40 cycles, 
with each cycle consisting of 5 s at 95℃ and 10 s at 
60℃. Using beta-actin as the internal control, relative 
quantitation was performed using the standard curve 
method. The level of beta-actin expression was 
assumed to be the same in JAR and JEG-3 cells, and 
the relative ratio of gene expression in JEG-3 cells 
was determined with gene expression in JAR cells 
assigned at a value of 1.
Western blot analysis
The JAR and JEG-3 cells were seeded on 24-well 
plates （2×10 5 cells/well） and dissolved 2 days later 
by adding 1×SDS loading buffer. The cell lysate was 
boiled for 5 min at 95℃, then electrophoresed through 
Mini-PROTEAN® TGXTM Precast Gels （Bio-Rad Lab-
oratories, Hercules, CA, USA）, and transcription was 
performed on a polyvinylidene difluoride membrane. 
Blocking was performed using 5％ skim milk, and the 
membrane was soaked in primary antibody diluted 
with blocking buffer and incubated overnight at 4℃. 
Anti-LAT1 antibodies were diluted 1,000-fold, and 
anti-beta-actin, clone C4 antibody （EMD Millipore, 
Billerica, MA, USA） was diluted 3,000-fold for use. 
Anti-mouse IgG-HRP antibody （GE Healthcare, Chi-
cago, IL, USA） was diluted 3,000-fold and used as the 
secondary antibody. The membrane was developed 
with SuperSignal West Pico Chemiluminescent Sub-
strate （Thermo Fisher Scientific, Inc., Waltham, MA, 
USA）, and images were obtained with an ImageQuant 
LAS 4000 imager （Fuji Film, Tokyo, Japan）. A solu-
tion of cells that persistently expressed LAT1 
（S2-LAT1） was used as the positive control for 
LAT18）. A solution of cells that persistently expressed 
LAT2 （S2-LAT2） was used as the negative control 8）.
［14C］Leucine uptake test
JAR and JEG-3 cells were seeded （3×10 5 cells/
well） on 24-well plates coated with poly-L-lysine 
（Corning Incorporated, Corning, NY, USA） and grown 
for 2 days. Hank’s balanced salt solution （HBSS） 
［125 mM NaCl, 4.8 mM KCl, 25 mM HEPES, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 1.3 mM CaCl2, and 5.6 mM 
glucose （pH 7.4）］ or sodium-free HBSS with 125 mM 
C5H14ClNO added instead of NaCl was used in the 
Table 1　Sequence of primers used for RT-PCR
Primer Forward （5’ to 3’） Reverse （5’ to 3’）
LAT1 tgcctgtgttcttcatcctg cctcctggctatgtctcctg
LAT2 gccctcaccttctccaacta aatgcattctttggctccag
LAT3 cacgctactgcaagatccaa agaagggctctcctttcagg
LAT4 aaatttggccttcactgtgg acgacgatgaaggagacacc
4F2hc cagaaggatgatgtcgctca ccagtggcggatataggaga
b-actin gctgcttttaactctggtaa cgcggccatcacgccacagt
Table 2　The primer sequences used for quantitative RT-PCR
Primer Forward （5’ to 3’） Reverse （5’ to 3’）
LAT1 actcaggaccagatgtccgtctc cgctgtgaagtctgtccatgtg
LAT2 tgctggacagatagtccttcg ggaacagcaggttgatcttg
LAT3 tgtgttcgccttgcttcag gagtgagaatagcaggaggc
LAT4 ctgaaggagtgtgaagacgc Tgatcttctggatctgccg
4F2hc atgagattggcctggatgc aagctggactcatcccacag
b-actin ctggcatcgtgatggactccgg gtggatgccacaggactccatg
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uptake test. The cells were washed twice in 1 mL of 
HBSS warmed to 37℃ and preincubated for 10 min. 
HBSS supplemented with 1 µM of ［14C］-leucine 
（Moravek, Brea, CA, USA） was then added, and incu-
bated for 1, 2, 5, 10, and 30 min. After incubation, the 
cells were washed twice with cold HBSS and dis-
solved with 0.1N NaOH. The radioactivity in the cell 
lysate was measured using an LSC-7200 liquid scintil-
lation counter （Hitachi Aloka Medical America, Inc./
Hitachi Ltd., Tokyo, Japan）. In addition, the protein 
content of the cell lysate was measured using the 
Pierce BCA Protein Assay Kit （Thermo Fisher Scien-
tific Inc.）, and protein normalization was performed.
In the test of leucine uptake inhibition by JPH203, 
JPH203 （0.001, 0.01, 0.1, 1, and 10 µM） was added to 
1 µM ［14C］-leucine solution using sodium-free HBSS, 
and the leucine uptake in 1 min was examined. A solu-
tion of 0.1％ DMSO/1％ EtOH was added as the con-
trol.
Cell proliferation test
To evaluate the proliferation-inhibiting effect of 
JPH203, cell proliferation over time was evaluated by 
measuring cell counts. JAR cells （1×10 4 cells/well） 
and JEG-3 cells （2×10 4 cells/well） were seeded on 
24-well plates, and culture solutions containing 10, 30, 
and 100 µM JPH203 were substituted the following 
day. A culture solution containing 0.1％ DMSO/1％ 
EtOH was used as the control. Cell counts were mea-
sured using a TC20 Automatic Cell Counter （Bio-Rad 
Laboratories） immediately after, and also on 2 and 4 
days after culture solution replacement.
Cell activity measurement
To evaluate cell activity after the addition of 
JPH203, cell activity was measured by the fluores-
cence method using Alamar Blue （Bio-Rad Laborato-
ries）. JAR cells （1×103 cells/well） and JEG-3 cells （2
×103 cells/well） were seeded on 96-well plates, and 
100 µL/well of JPH203 at different concentrations （10, 
30, and 100 µM） and a control culture solution con-
taining 0.1％ DMSO/1％ EtOH were substituted the 
following day. Ten microliters per well of Alamar 
Blue were added immediately after （0 days） and also 
on 2 and 4 days after culture solution replacement, 
the cells were incubated under 5％ CO2 at 37℃ for 3 
h, and fluorescence intensity was measured （measure-
ment wavelengths used：544 nm excitation wave-
length, 590 nm fluorescence emission wavelength）. 
Measurements were also performed only for wells 
with culture solution that had JPH203 added, and the 
value yielded by subtracting the fluorescence intensity 
of wells with culture solution alone from the fluores-
cence intensity of the test wells was evaluated.
Statistical analysis
In the quantitative RT-PCR analysis, Student’s 
t-test was used for JAR cell expression. A multigroup 
analysis of the results of the cell proliferation test and 
cell activity measurements was performed by analysis 
of variance （ANOVA） using SPSS Statistics version 
24 （IBM Corp., Armonk, NY, USA）, and the groups 
were compared using the Bonferroni method. The 
means and standard errors were shown for the data. 
A p-value ＜0.05 was considered significant.
RESULTS
Expressions of LATs and 4F2hc in cultured choriocar-
cinoma cells
RT-PCR was performed using mRNA extracted 
from JAR and JEG-3 cells to examine whether LATs 
were present in these lines of cultured choriocarcino-
ma cells using the expressions of LATs and 4F2hc in 
lines of cultured choriocarcinoma cells （Fig. 1A）. RT-
PCR of JAR cells showed clear bands for LAT1 , 
LAT4, and 4F2hc. A weak band was seen for LAT2. 
With JEG-3 cell RT-PCR, clear bands were detected 
for LAT1, LAT2, LAT4, and 4F2hc. In addition, 
quantitative RT-PCR was performed using the same 
mRNA to assess whether there were differences 
between the cells in the expression of LAT mRNA 
（Fig. 1B）. With the expression of LATs in JAR cells 
assigned at a value of 1, LAT1 expression in JEG-3 
cells was 0.8-fold, which was significantly lower. The 
level of LAT2 expression in JEG-3 cells was 3.5-fold 
higher. The expressions of LAT3 and LAT4 were 
lower in JEG-3 cells than in JAR cells （LAT3：0.8-
fold, LAT4：0.4-fold）. No difference in 4F2hc expres-
sion were seen between JAR and JEG-3 cells. LAT1 
expression in JAR and JEG-3 cells was also examined 
by Western blot analysis. Although the homology 
between LAT1 and LAT2 is 50％5）, it was deter-
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mined that the LAT1 antibody used in this study rec-
ognized only LAT1. Consequently, LAT1 protein 
expression was determined for both JAR and JEG-3 
cells （Fig. 2）.
Leucine uptake and its inhibition by JPH203 in a line 
of cultured choriocarcinoma cells
To examine whether LAT-mediated amino acid 
uptake occurs in JAR and JEG-3 cells, leucine uptake 
tests were performed using HBSS containing sodium 
and sodium-free HBSS, and whether sodium-indepen-
dent amino acid transport occurs in these cells was 
examined. In both JAR and JEG-3 cells, no difference 
in leucine uptake was seen as a result of the differ-
ence in HBSS （Fig. 3A）. That is, sodium-independent 
leucine transport was shown to exist in JAR and 
Figure 1　 Expression of LATs and 4F2hc in 
JAR and JEG-3 cells
A：RT-PCR of LATs. RT-PCR of LATs 
was performed using collected mRNA from 
JAR and JEG-3 cells. In RT （＋） side lane, 
synthesized cDNA was added to the reac-
tion mixture. In RT （−） side lane, mRNA 
was added. Primers’ sequence was shown in 
Table 1 . B：Quantitative PCR of LATs. 
mRNA expression of LATs and 4F2hc was 
quantified by realtime PCR. Expression level 
was indicated as expression relative to JAR. 
Error bars represent±standard error （SE） 
for triplicate experiments.
Figure 2　Western blotting of LAT1
Whole cell proteins were extracted from non-treated 
JAR and JEG-3 cel ls , LAT1 expressing cel ls 
（S2-LAT1）, LAT2 expressing cells （S2-LAT2） and 
mock cells （S2-mock）. Lysate of LAT1 expressing 
cells was considered a positive control. Blotting for 
b-actin serves as loading controls.
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JEG-3 cells.
Next, a leucine uptake test with JPH203 loaded was 
performed to examine whether the sodium-indepen-
dent leucine transport in JAR and JEG-3 cells is 
mediated by LAT1. JPH203-concentration-dependent 
inhibition of leucine uptake was seen in both JAR and 
JEG-3 cells （Fig. 3B）. The IC50 was calculated to be 
0.408 µM for JAR cells and 0.475 µM for JEG-3 cells. 
These results showed that LAT1-mediated leucine 
transport exists in JAR and JEG-3 cells.
Proliferation-inhibiting effect of JPH203
To examine whether JAR and JEG-3 cell prolifera-
tion is inhibited by the inhibition of LAT1-mediated 
amino acid transport, cell counts were measured after 
JPH203 loading （Fig. 4）. No difference in the JAR cell 
count was seen immediately after culture solution 
replacement, but the cell count was significantly lower 
in the 100 µM group than in the control group 2 days 
after replacement. The cell count was also significant-
ly lower in the 100 µM group than in the control 
group 4 days after replacement. However, cell counts 
in the 10 and 30 µM groups were nearly identical to 
those in the control group. With JEG-3 cells, no 
changes in the cell count were seen due to the addi-
tion of JPH203 immediately after or 2 days after cul-
Figure 3　Leucine uptake of JAR and JEG-3 cells and inhibition by JPH203
A：Time courses of leucine uptake were examined with HBSS containing Na （Normal 
HBSS） and Na free HBSS. One µM ［14C］-Leucine uptake by JAR and JEG-3 cells was 
measured during a 30 minutes incubation. B：Inhibition of leucine uptake by JPH203 in 
JAR and JEG-3 cells. JAR and JEG-3 cells were incubated with ［14C］-Leucine and 
0.001-10 µM JPH203 for 1 minute. Data are shown as means±SE.
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ture solution replacement. However, a JPH203 concen-
tration-dependent decrease in cell count was seen 4 
days after replacement.
Changes in cell activity due to JPH203
Cell activity following treatment with JPH203 was 
examined over time to determine whether amino acid 
transport by LAT1 is involved in the activity of JAR 
and JEG-3 cells （Fig. 5）. The activity of the JAR cells 
in the groups with 10 and 30 µM added increased on 
all of the measurement days. In the group with 100 
µM added, cell activity decreased immediately after 
culture solution replacement （3 h after）, but it did not 
differ significantly compared with the control from 2 
days after replacement onward. The activity of JEG-3 
cells decreased significantly in the group with 10 µM 
added immediately after and 2 days after culture solu-
tion replacement. The activity of cells in the groups 
with 30 and 100 µM added decreased significantly 
immediately after and 2 and 4 days after replacement.
Figure 4　Growth inhibitory effect of JPH203
The cells were treated with 0, 10, 30 and 100µM JPH203 for 0, 2 and 4 days. After 
incubation, cells were trypsinized and counted by auto cell counter. Data are shown 
as means±SE. （＊：p＜0.05, #：p＜0.01 compared to the control group）
Figure 5　Metabolic activities of JPH203-treated JAR and JEG-3 cells
JAR and JEG-3 cells were treated with 0, 10, 30 and 100 µM JPH203 for 0, 2 and 4 
days. The metabolic activities were determined by Alamar Blue solution. Data are 
shown as means±SE. （＊：p＜0.05, #：p＜0.01 compared to the control group）
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DISCUSSION
In this study, it was found that amino acids are 
transported by LAT1 in two kinds of choriocarcinoma 
cell lines, JAR cells and JEG-3 cells. Moreover, these 
cell lines showed different responses of cytostasis and 
cell activity changes to LAT1 inhibition.
The quantitative RT-PCR showed that the expres-
sions of LAT1, 3 and 4 were slightly but significantly 
higher in the JAR cells than in the JEG-3 cells. On 
the contrary, the expression of LAT2 was higher in 
the JEG-3 cells than in the JAR cells. It is generally 
known that LAT2 and 4 are expressed in normal 
cells , while the expressions of LAT1 and 3 are 
increased in cancer cells 2）. Furthermore, it has been 
reported that the JAR cells proliferate faster and pro-
duce more human chorionic gonadotropin than the 
JEG-3 cells 14）. From these, it may be said that the 
JAR cells maintain the characteristics of choriocarci-
noma in comparison with the JEG-3 cells. In the 
Western blotting, the LAT1 protein could be identi-
fied in the JEG-3 cells as well as the JAR cells. The 
LAT1/b-actin ratios were comparable between the 
two cell lines.
The leucine transport of the JAR cells or the JEG-3 
cells was not affected by the existence or the absence 
of Na in HBSS. It is suggested that the leucine trans-
port by LATs plays a substantial role in the amino 
acid transport by cultured choriocarcinoma cell lines. 
The IC50 levels of the leucine uptake were reportedly 
0.06 µM in the human intestinal tract cancer cell line 
（HT29）9） and 0.79 µM in the human oral cancer cell 
l ine （YD-38）8）. In this study, the IC50 levels of 
JPH203 for the leucine uptake inhibition were lower 
in both the JAR cells and in the JEG-3 cells compared 
to the YD-38 cells. Thus, it is indicated that the inhib-
itory action of JPH203 on leucine uptake is higher in 
the choriocarcinoma cell lines than in the YD-38 cells.
In addition to the HT-29 cells, JPH203 is known to 
inhibit the proliferation of many other neoplastic 
cells 8〜10）. For example, it has been reported that the 
100 µM JPH203 reduced the number of HT-29 cells 
to 10％ of the control after four days 8） and also 
reduced the number of YD-38 cells to 40％ of the 
control 9）. However, more than half of the JAR and the 
JEG-3 cells had lived after four days giving 100 µM 
JPH203 as compared with the control （Figure 4）, 
indicating that the suppressant effect of JPH203 is 
less potent in the JAR and the JEG-3 cells than in the 
HT-29 or the YD-38 cells. The role of LAT1 in cell 
proliferation may be different between these cell lines 
（HT-29 and YD-38） and the choriocarcinoma cell 
lines. It is known that amino acids are not only used 
as constituents or nutrients in cancer cells, but also 
work as a secondary messengers which promotes the 
proliferation of cancer cells 2）. A more detailed exami-
nations are necessary to clarify whether the difference 
in the effect of JPH203 on cell proliferation is caused 
by the depletion of nutrients or by the signal trans-
duction disturbance in the cancer cells.
The IC50 levels of JPH203 calculated by the leucine 
uptake experiment were comparable between the 
JAR cells and the JEG-3 cells. On the other hand, the 
cytostatic effect of JPH203 was concentration-depen-
dent in the JEG-3 cells, while the effect was only seen 
by a high-concentration of JPH203 in the JAR cells 
（Figure 4）. Considering that the JAR cells have high-
er proliferative capacity than the JEG-3 cells, it is 
imagined that the amino acid level necessary for cell 
proliferation is more in the JAR cells than in the 
JEG-3 cells （Figure 3A）. However, because the amino 
acid uptake level was higher in the JEG-3 cells than 
in the JAR cells, it is suggested that these two cell 
lines have different demand characteristics for amino 
acids. The higher expression of LAT2 in the JEG-3 
cells than in the JAR cells supports a higher demand 
of amino acids in the JEG-3 cells （Figure 1B）. In 
addition, because JPH203 was added to the culture 
medium and the RPMI-1640 medium used for the 
JAR cells contains more amino acids than the MEM 
medium used for the JEG-3 cells, it is possible that 
the higher amino acid levels in the medium caused an 
increased amino acid uptake by the JAR cells than 
the JEG-3 cells even under the existence of JPH203. 
The experiments were performed in the environment 
that the cells are easy to multiply, but the examina-
tion under the condition of same amino acid availabili-
ty for each cell lines may provide different results.
The cell activity evaluation using Alamar Blue 
reflecting the reduction power of viable cells is a 
quantitative measurement of the cell proliferation and 
is often performed in a purpose same as cell count 15）. 
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However, we examined the cell count and the cell 
activity measurement separately to evaluate the 
effects of amino acid transport by LAT1 on cell activi-
ty in this study. Interestingly, the concentration-
dependent decreasing effect of JPH203 was seen with-
in a day in the JEG-3 cells. Whereas, the cell activity 
started to increase following the addition of JPH203 at 
concentrations of 10 and 30 µM on the day 0 in the 
JAR cell （Figure 5）. It is thought that the JEG-3 cells 
could not maintain the metabolism of the cells when 
the amino acid transport was inhibited by JPH203, 
which resulted in the decrease of cell activity. On the 
other hand, the amino acid transport inhibition by 
JPH203 may have induced the autophagy mechanism 
which possibly increased the JAR cell activity. It is 
reported that the cell activity of the human cell line 
rises with the induction of autophagy mechanism16）, 
and it is speculated that the autophagy mechanism is 
easier to be induced in the JAR cells than in the 
JEG-3 cells. However, the decrease in cell count by 
100 µM JPH203 in comparison with the control start-
ed to be seen on the 2nd day in the JAR cells, which 
was earlier than the occurrence of cytostatic effect by 
JPH203 in the JEG-3 cells. Thus, the high concentra-
tion JPH203 was shown to restrain cell proliferation 
irrespective of the kind of choriocarcinoma cell line. It 
became clear in this study that the cell activities of 
the JAR cells and the JEG-3 cells respond differently 
to the low concentration JPH203, but the high concen-
tration JPH203 can restrain the cell proliferation of 
these two kinds of cultured choriocarcinoma cells.
CONCLUSION
The present study demonstrated that amino acid 
transport by LAT1 functions in two kinds of chorio-
carcinoma cell lines. In addition, highly-concentrated 
JPH203 showed an inhibitory effect on the prolifera-
tion of choriocarcinoma cell lines. Furthermore, it was 
suggested that the amino acid transport by LAT1 has 
complicated and various roles in the activity of chorio-
carcinoma cells.
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